Prudentia Sciences, a Cambridge, MA–based AI-native platform for life sciences due diligence and dealmaking, has raised $20 million in a Series A round, bringing its total funding to $27 million.
Investors
The round was led by McKesson Ventures, with participation from SignalFire and existing investors Iaso Ventures, Virtue, and GV.
McKesson Ventures is the strategic venture capital arm of McKesson Corporation, one of the world's largest healthcare services companies. Based in San Francisco, the firm focuses on investing in early- and growth-stage companies that are transforming the healthcare ecosystem through technology and innovative services.
Prudentia Sciences Use of Funds
The company will use the funding to expand product capabilities, enhance intelligence for technical and non-technical diligence, and scale commercial operations, including expansion into Asia-Pacific and Europe.
About Prudentia Sciences
Led by CEO Sadiqa Mahmood, Prudentia Sciences is a technology company that offers an AI-native platform that helps pharmaceutical, biotech, and financial organizations evaluate breakthrough medicines accurately. It provides an AI-powered platform designed to accelerate and improve decision-making in life sciences dealmaking, drug asset evaluation, and investment strategy. Prudentia's human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries.
Funding Details
Company: Prudentia Sciences
Raised: $20.0M
Round: Series A
Funding Date: January 2026
Lead Investor: McKesson Ventures
Additional Investors: SignalFire, Iaso Ventures, Virtue, GV
Company Website: https://www.prudentiasciences.com/
Software Category: AI Healthcare / Life Sciences Deal Intelligence
Source: https://www.businesswire.com/news/home/20260106972777/en/